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background: Although statin therapy is beneficial for vascular diseases, the relationship between specific statin therapy and the incidence of new-
onset diabetes mellitus (DM) remains uncertain. We evaluated the impact of Pitavastatin therapy on the development of new-onset DM from 3-year 
clinical follow up data in Asian population.
methods: From January 2004 to September 2009, a total of 3,147 consecutive patients who did not have DM were enrolled. New-onset DM was 
defined as having a fasting blood glucose ≥126mg/dL or HbA1c ≥6.5%. Baseline characteristics between the Pitavastatin and the control group 
were propensity score matched (PSM, C-statics=0.868). Three-year incidence of new-onset DM was compared between the two groups.
results: At baseline, patients in the Pitavastatin group had higher prevalence of elderly, male gender, dyslipidemia, coronary artery disease, 
smoking history, alcoholic history, higher levels of total cholesterol, triglyceride and LDL-C. The incidence of new-onset DM was higher in the 
Pitavastatin group at 3 years (6.8% vs. 2.0%, p<0.001). Following PSM (C-statics=0.868), the 2 groups were well balanced and 3-year follow up 
showed higher incidence of new-onset DM in the Pitavastatin group (8.4% vs. 0%, p=0.004, figure).
conclusions: In our study, chronic pitavastatin use was associated with increased incidence of new-onset DM at 3 years.
 
